Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate, vecabrutinib, is a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK) currently undergoing Phase 1b/2 clinical trials for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. Additionally, Sunesis is advancing SNS-510, which is in preclinical studies for various tumor types, alongside partnered programs such as TAK-580, a pan-Raf inhibitor in Phase 1 trials for pediatric low-grade glioma, and vosaroxin, an anti-cancer quinolone derivative. The company has established collaborations, including an agreement with Biogen Idec MA, Inc. for small molecule BTK inhibitors and a licensing agreement with Takeda Pharmaceutical Company Limited for preclinical PDK1 inhibitors. Founded in 1998 and headquartered in South San Francisco, California, Sunesis Pharmaceuticals is committed to innovative approaches in the ongoing fight against cancer.